BioMedPartners

Miracor Medical operates as a medical device company. It develops and commercializes a pressure-controlled intermittent coronary sinus occlusion (PiCSO) impulse system for cardiac surgeons to facilitate the PiCSO treatment for myocardial infarction/heart attack patients undergoing coronary artery bypass grafting surgery. Miracor Medical offers a therapy for improving micro-vascular perfusion functions through the coronary sinus. Werner Mohl founded it in 2008, with its headquarters in Awans in Belgium.

Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.

Aleva Neurotherapeutics SA develops implantable directional deep brain stimulation (DBS) systems. It offers directSTIM, a DBS system that uses an array of directional microelectrodes to focus electrical stimulation decreasing the need for exact positioning; spiderSTIM, a DBS diagnostic system that encompasses 3-dimensional areas in a brain target, and record and stimulate the region in order to provide a diagnostic tool; and cortiSTIM, a device for cortical stimulation. The company was founded in 2008 and is based in Lausanne, Switzerland.

Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors as a new class of drug targets.The company's immunotherapy technologies tackle diseases on the genetic level and focuses on disease suppressing genes., it uses genomics to develop innovative therapies for patients affected by severe diseases.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Tubulis GmbH researches, designs, and develops protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. The company develops transformative antibody-drug conjugates (ADCs), which helps to identify novel protein-drug combinations for therapeutic application. The company was founded in 2019 and is based in Munich, Germany.

Dolthera GmbH is a biopharmaceutical company that is developing an innovative class of nucleic-acid-based anti-inflammatory drugs. These drugs, based on oligonucleotides that act as decoys for disease-related transcription factors are all directed against biologically validated targets in major chronic diseases with high unmet medical need. With this business concept and the underlying patent-protected technologies, AVONTEC won in 2003 the prestigious German Founders Award that is backed by McKinsey & Company. Initially, the Company has chosen to focus its patented technology on chronic inflammatory respiratory system and skin diseases. AVONTEC currently has five programs in respiratory disease, skin disease, transplant rejection, cardiovascular disease and autoimmune disease under development. All these indications represent areas with high unmet medical need and strong commercial potential.

Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

Noema Pharma AG operates as a biotechnology company. The company develops therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. It develops and commercializes therapies for conditions affecting the nervous system, including Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. Noema Pharma AG was founded in 2019 and is based in Basel, Switzerland.

Inotrem S.A discovers and develops novel treatments in the field of inflammatory pathologies with a focus on critical care. Its technology includes a TREM-1 inhibitor, nangibotide (LR12), that aims to control excessive inflammation in severe sepsis patients. The company was founded in 2013 and is based in Paris, France.

Alentis Therapeutics AG develops and manufactures medications to treat advanced liver diseases. It develops medications for liver fibrosis, cirrhosis, and liver cancer. The company was founded in 2019 and is based in Basel, Switzerland.

SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also develops preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. 4-Antibody AG was founded in 2002 and is based in Basel, Switzerland.

Sequana Medical NV, a commercial stage medical device company, focuses on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure in Switzerland, Germany, and internationally. Its products include alfapump, a treatment solution for the management of liver refractory ascites and malignant ascites; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with volume overload due to heart failure. The company was founded in 2006 and is headquartered in Ghent, Belgium.

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.

Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy. The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Aleva Neurotherapeutics SA develops implantable directional deep brain stimulation (DBS) systems. It offers directSTIM, a DBS system that uses an array of directional microelectrodes to focus electrical stimulation decreasing the need for exact positioning; spiderSTIM, a DBS diagnostic system that encompasses 3-dimensional areas in a brain target, and record and stimulate the region in order to provide a diagnostic tool; and cortiSTIM, a device for cortical stimulation. The company was founded in 2008 and is based in Lausanne, Switzerland.

Thommen Medical develops, produces and sells dental implants under the brand name SPI (Swiss Precision Implant) as well as biomaterial solutions for bone and tissue regeneration. Thommen Medical Implants are designed to be precise and easy to use, thanks to collaboration with leading scientific and dental clinicians.

Idiag is a specialist in interfacing research & development with sales and marketing. A central business aim is to convert innovative ideas on medical technology into products ready to market. Therefore Idiag offers to Universities and Innovation Centres, to take over final development, production and marketing for their unused medical product potential. Furthermore Idiag offers to manufacturer of high quality supplementing products, to act as reseller. Idiag then uses its existing resources, networks and excellence for market penetration and sales, within Switzerland and Germany.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.

Noema Pharma AG operates as a biotechnology company. The company develops therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. It develops and commercializes therapies for conditions affecting the nervous system, including Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. Noema Pharma AG was founded in 2019 and is based in Basel, Switzerland.

Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.

Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small molecule drugs and other compounds. In particular their platform allows the creation of chemistries that recapitulate the themes found in natural products, but without the disadvantages of those approaches.

Middle Peak Medical is a privately held medical device company focused on the development and commercialization of a novel technology to treat mitral valve disease. The company’s proprietary device has application in both percutaneous catheter-based intervention, and in minimally invasive or open-heart cardiac surgery.

Sequana Medical NV, a commercial stage medical device company, focuses on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure in Switzerland, Germany, and internationally. Its products include alfapump, a treatment solution for the management of liver refractory ascites and malignant ascites; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with volume overload due to heart failure. The company was founded in 2006 and is headquartered in Ghent, Belgium.

Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

TOLREMO therapeutics AG, a biotechnology company, develops drug discovery engine and therapies to patients with cancer. The company was incorporated in 2017 and is based in Muttenz, Switzerland.

ImevaX GmbH develops specific vaccines against pathogens, which cause chronic infectious diseases. The company creates specific vaccines against immune evasion factors to control chronic and nosocomial infections. It offers vaccine against helicobacter pylori, which colonizes the stomach and is the cause of ulcer disease and gastric cancer in humans. The company was founded in 2014 and is based in Munich, Germany.

Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.

Sequana Medical NV, a commercial stage medical device company, focuses on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure in Switzerland, Germany, and internationally. Its products include alfapump, a treatment solution for the management of liver refractory ascites and malignant ascites; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with volume overload due to heart failure. The company was founded in 2006 and is headquartered in Ghent, Belgium.

Tubulis GmbH researches, designs, and develops protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. The company develops transformative antibody-drug conjugates (ADCs), which helps to identify novel protein-drug combinations for therapeutic application. The company was founded in 2019 and is based in Munich, Germany.

Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

Lumavita AG, a biopharmaceutical company, engages in the development and commercialization of novel anti-infectives for women's health. Its products include FemiFect, an antibiotic to treat infections known to cause vaginitis, such as bacteria, fungi, and protozoa; and SPK-601 that is for the treatment of human papilloma virus (HPV) and herpes simplex virus (HSV). The company markets its products through distributors. Lumavita AG was formerly known as Shogoo Pharmaceuticals, AG and changed its name to Lumavita AG in December, 2007. The company was founded in 2008 and is based in Basel, Switzerland. Lumavita AG operates as a subsidiary of Shogoo Pharmaceuticals KK.

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Aleva Neurotherapeutics SA develops implantable directional deep brain stimulation (DBS) systems. It offers directSTIM, a DBS system that uses an array of directional microelectrodes to focus electrical stimulation decreasing the need for exact positioning; spiderSTIM, a DBS diagnostic system that encompasses 3-dimensional areas in a brain target, and record and stimulate the region in order to provide a diagnostic tool; and cortiSTIM, a device for cortical stimulation. The company was founded in 2008 and is based in Lausanne, Switzerland.

Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases. Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart's goals are to improve a patient’s quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart’s leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

Allecra Therapeutics GmbH develops pharmaceuticals to treat gram-negative multi drug-resistant bacterial infections. The company was founded in 2013 and is based in Weil am Rhein, Germany.

AYOXXA is a biotech company commercializing innovative technology developed at the National University of Singapore (NUS). AYOXXA’s patented technology platform is producing a new generation of biochips – merging biology with IT. This allows the biochip to accumulate large numbers of applications – measuring multiple protein markers for cancer, allergies, cardiovascular and infectious diseases – in a single test.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Curetis AG focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases. Curetis integrates today´s molecular diagnostics laboratory into one instrument for the detection of severe bacterial infections as a first target application. However, the universal platform will also allow the future expansion into other clinical applications with additional market opportunities beyond infectious diseases.

TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.

TOLREMO therapeutics AG, a biotechnology company, develops drug discovery engine and therapies to patients with cancer. The company was incorporated in 2017 and is based in Muttenz, Switzerland.

Cardior Pharmaceuticals is a biotechnology company that engages in the development of non-coding RNA based therapeutics for the treatment and prevention of heart disease. It focuses on developing CDR-132X, an oligonucleotide-based inhibitor of a molecular master switch (microRNA) controlling pathological alterations of the heart following stress or injury. Cardior Pharmaceuticals is a planned academic spin-off developing new therapeutics for the treatment and prevention of heart disease - the number one cause of death in the western world.

Activaero GmbH, a drug delivery company, engages in the research, development, manufacture, and marketing of controlled breathing technologies that are used for the delivery of inhaled therapeutic agents to the human lung and various lung regions. It offers AKITA, a controlled breathing device with smart card technology for the pulmonary delivery of inhaled therapeutics; and Watchhaler, an inhalation device tailored to the needs of children who need to take inhaled medication. The company also provides AKITA², a controlled breathing technology for the pulmonary delivery of inhaled therapeutics in the clinical trial setting; and LimiX, a first flow limitation valve that controls the flow rate. In addition, it offers measurement and diagnostic technologies for use in laboratory settings, including a system to measure the properties of aerosols in a minute. Further, the company provides contract development services for devices to use in clinical trials; and clinical trial logistics services. It markets its products through distributors. Activaero GmbH was founded in 2004 and is based in Gemunden, Germany. It also has locations in Munich, Germany; and Dublin, Ohio.

TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.

Tubulis GmbH researches, designs, and develops protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. The company develops transformative antibody-drug conjugates (ADCs), which helps to identify novel protein-drug combinations for therapeutic application. The company was founded in 2019 and is based in Munich, Germany.

Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly

Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.

Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

TOLREMO therapeutics AG, a biotechnology company, develops drug discovery engine and therapies to patients with cancer. The company was incorporated in 2017 and is based in Muttenz, Switzerland.

Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.

CareX SA is a biopharmaceutical company that develops novel treatments for metabolic and immune system disorders which includes diabetes and obesity. The company focuses on metabolic syndrome, a cluster of inter-related disorders of the body’s metabolism, including high blood pressure, high insulin levels, excess body weight, and abnormal cholesterol levels, that exposes individuals to the development of type 2 diabetes, heart diseases, and strokes. CareX SA is a France-based company that was founded in 2001 and the company was acquired by 7TM Pharma on May 24, 2006.

EyeSense AG develops ophthalmic diagnostic systems focusing on glucose testing for diabetic patients. They make blood glucose control easier and pain-free through innovative monitoring devices.

Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.

TOLREMO therapeutics AG, a biotechnology company, develops drug discovery engine and therapies to patients with cancer. The company was incorporated in 2017 and is based in Muttenz, Switzerland.

Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Inotrem S.A discovers and develops novel treatments in the field of inflammatory pathologies with a focus on critical care. Its technology includes a TREM-1 inhibitor, nangibotide (LR12), that aims to control excessive inflammation in severe sepsis patients. The company was founded in 2013 and is based in Paris, France.

Miracor Medical operates as a medical device company. It develops and commercializes a pressure-controlled intermittent coronary sinus occlusion (PiCSO) impulse system for cardiac surgeons to facilitate the PiCSO treatment for myocardial infarction/heart attack patients undergoing coronary artery bypass grafting surgery. Miracor Medical offers a therapy for improving micro-vascular perfusion functions through the coronary sinus. Werner Mohl founded it in 2008, with its headquarters in Awans in Belgium.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Activaero GmbH, a drug delivery company, engages in the research, development, manufacture, and marketing of controlled breathing technologies that are used for the delivery of inhaled therapeutic agents to the human lung and various lung regions. It offers AKITA, a controlled breathing device with smart card technology for the pulmonary delivery of inhaled therapeutics; and Watchhaler, an inhalation device tailored to the needs of children who need to take inhaled medication. The company also provides AKITA², a controlled breathing technology for the pulmonary delivery of inhaled therapeutics in the clinical trial setting; and LimiX, a first flow limitation valve that controls the flow rate. In addition, it offers measurement and diagnostic technologies for use in laboratory settings, including a system to measure the properties of aerosols in a minute. Further, the company provides contract development services for devices to use in clinical trials; and clinical trial logistics services. It markets its products through distributors. Activaero GmbH was founded in 2004 and is based in Gemunden, Germany. It also has locations in Munich, Germany; and Dublin, Ohio.

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

TOLREMO therapeutics AG, a biotechnology company, develops drug discovery engine and therapies to patients with cancer. The company was incorporated in 2017 and is based in Muttenz, Switzerland.

Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.

Humedics, based in Berlin, focuses on rapid and precise liver function measurement using LiMAx, its innovative breath analysis technology. This easy-to-use bedside test provides doctors with accurate information to support decision making in tailoring the medical treatment to the individual level of each patient and to improve patient outcomes. LiMAx has already been used on thousands of patients and the company is currently expanding its operation globally.

Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.

Alentis Therapeutics AG develops and manufactures medications to treat advanced liver diseases. It develops medications for liver fibrosis, cirrhosis, and liver cancer. The company was founded in 2019 and is based in Basel, Switzerland.

Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small molecule drugs and other compounds. In particular their platform allows the creation of chemistries that recapitulate the themes found in natural products, but without the disadvantages of those approaches.

TRiCares SAS, a medical device company, develops catheter-based valve replacement system for treatment of tricuspid valve regurgitation. It develops a transcatheter-based tricuspid valve replacement system for treatment of disease that avoids open heart surgery and heart valve diseases. The company was founded in 2013 and is based in Paris, France with an additional office in Munich, Germany.

Miracor Medical operates as a medical device company. It develops and commercializes a pressure-controlled intermittent coronary sinus occlusion (PiCSO) impulse system for cardiac surgeons to facilitate the PiCSO treatment for myocardial infarction/heart attack patients undergoing coronary artery bypass grafting surgery. Miracor Medical offers a therapy for improving micro-vascular perfusion functions through the coronary sinus. Werner Mohl founded it in 2008, with its headquarters in Awans in Belgium.

Vaximm is focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Their initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Vaximm has shown impressive anti-tumor activity in various animal studies and will enter first human clinical trials in 2011.

Alentis Therapeutics AG develops and manufactures medications to treat advanced liver diseases. It develops medications for liver fibrosis, cirrhosis, and liver cancer. The company was founded in 2019 and is based in Basel, Switzerland.

Spinal Cord Therapeutics GmbH develops treatments for spinal cord injury. Spinal Cord Therapeutics focuses on the treatment of traumatic injury to the central nervous system.

Symetis is a Swiss Company developing innovative minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases. Symetis is dedicated to improving patient care and safety by offering simple, accurate solutions for heart valve replacement. Its proprietary Acurateâ„¢Aortic Valve Replacement System features a unique self-positioning design providing facile implant positioning and alignment as well as unrivalled ease of use.

Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.

Cardior Pharmaceuticals is a biotechnology company that engages in the development of non-coding RNA based therapeutics for the treatment and prevention of heart disease. It focuses on developing CDR-132X, an oligonucleotide-based inhibitor of a molecular master switch (microRNA) controlling pathological alterations of the heart following stress or injury. Cardior Pharmaceuticals is a planned academic spin-off developing new therapeutics for the treatment and prevention of heart disease - the number one cause of death in the western world.

SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

Miracor Medical operates as a medical device company. It develops and commercializes a pressure-controlled intermittent coronary sinus occlusion (PiCSO) impulse system for cardiac surgeons to facilitate the PiCSO treatment for myocardial infarction/heart attack patients undergoing coronary artery bypass grafting surgery. Miracor Medical offers a therapy for improving micro-vascular perfusion functions through the coronary sinus. Werner Mohl founded it in 2008, with its headquarters in Awans in Belgium.

Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.

Curetis AG focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases. Curetis integrates today´s molecular diagnostics laboratory into one instrument for the detection of severe bacterial infections as a first target application. However, the universal platform will also allow the future expansion into other clinical applications with additional market opportunities beyond infectious diseases.

Aleva Neurotherapeutics SA develops implantable directional deep brain stimulation (DBS) systems. It offers directSTIM, a DBS system that uses an array of directional microelectrodes to focus electrical stimulation decreasing the need for exact positioning; spiderSTIM, a DBS diagnostic system that encompasses 3-dimensional areas in a brain target, and record and stimulate the region in order to provide a diagnostic tool; and cortiSTIM, a device for cortical stimulation. The company was founded in 2008 and is based in Lausanne, Switzerland.